Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML

Publisher： Karger

E-ISSN： 1421-9662|127|3|152-155

ISSN： 0001-5792

Source： Acta Haematologica, Vol.127, Iss.3, 2012-01, pp. : 152-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Imatinib-Resistant CML Patients

By  

Oncology Research and Treatment, Vol. 30, Iss. 11, 2007-10 ,pp. : 574-580

Karger

Access to resources Recommend Favorite

Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 356-364

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 59-68

Karger

Access to resources Recommend Favorite

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis

By Griffin James D.  

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 112-117

Karger

Access to resources Recommend Favorite